First, we observed tumor molecular subtype switching from pre-treatment to post-treatment, with many tumors switching to Consensus stroma-rich, MDA p53 subtypes, an effect not associated with changes in tumor cellularity. This evidence concerns the gene TP53 and neoplasm.